Skip to main content
Erschienen in: BMC Neurology 1/2014

Open Access 01.12.2014 | Case report

Reversible Pisa syndrome associated to subdural haematoma: case-report

verfasst von: Pasquale Marchione, Aldo Spallone, Marcella Valente, Cristiano Giannone, Floriana De Angelis, Giuseppe Meco

Erschienen in: BMC Neurology | Ausgabe 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Pisa Syndrome or Pleurothotonus is a relatively rare truncal dystonia, characterized by tonic flexion of the trunk and head to one side with slight rotation of the body. Since frequently associated to specific drugs such as antipsychotics and cholinesterase inhibitors or to Parkinson Disease, a pathophysiological role of cholinergic-dopaminergic imbalance has been suggested. We report here the first case of Pisa Syndrome due to an extracerebral pathology as subdural haematoma.

Case presentation

A hypertensive patient was admitted to Our Department for subacute onset of tonic flexion and slight rotation of the trunk associated to progressive motor deficit in left upper limb after a mild head trauma without loss of consciousness occurred around three month before. No previous or current pharmacological interventions with antidepressant, neuroleptic or anticholinergic drugs were anamnestically retrieved. Familiar and personal history was negative for neurological disorders other than acute cerebrovascular diseases. Acutely performed cerebral MRI with DWI showed a voluminous right subdural haematoma with mild shift of median line. After surgical evacuation, both motor deficit and truncal dystonia were dramatically resolved. At one-year follow up, the patient did not develop any extrapyramidal and cognitive signs or symptoms.

Conclusions

According to many Authors, the occurrence of truncal dystonia during several pharmacologic treatments and neurodegenerative disorders (such as Alzheimer disease and parkinsonian syndromes) supported the hypothesis that a complex dysregulation of multiple neurotransmitter systems are involved. We suggest a possible role of basal ganglia compression in pathogenesis of truncal dystonia by means of thalamo-cortical trait functional disruption and loss of proprioceptive integration. A further contribution of the subcortical structure displacement that alters motor cortex connectivity to basal ganglia may be postulated.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1471-2377-14-149) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no financial and non-financial competing interests.

Authors’ contributions

PM performed the preoperative and postoperative clinical evaluation of the patients, collected both literature and patient data and imaging and drafted the manuscript; AS interpreted neuroimaging, carried out neurosurgical intervention as first operator and revised critically the manuscript; MV performed the clinical follow up at one year and helped to collected literature data and to draft the manuscript; Cristiano Giannone carried out the neurosurgical intervention as second operator and helped to draft the manuscript; FDA collected anamnestic data, helped the interpretation of neuroimaging and participated in the manuscript draft; GM interpreted neuroimaging, performed preoperative and postoperative clinical evaluation, revised critically the manuscript and finally approved the version to be published. All authors read and approved the final manuscript.
Abkürzungen
PS
Pisa Syndrome
PD
Parkinson Disease
iNPH
idiopathic Normal Pressure Hydrocephalus
SDH
Subdural haematoma
MRI
Magnetic Resonance Imaging
DWI
Diffusion Weighted Imaging
D2
type-2 dopamine receptors
5HT
type-2 5-HydroxyTriptamine
NE
norepinephrine receptors.

Background

First described by Ekbom in early 1972 [1], Pisa Syndrome (PS) or Pleurothotonus is a relatively rare global dystonia characterized by tonic flexion of the trunk and head to one side with slight rotation of the body [2]. Female gender, old age and organic brain disorders such as parkinsonisms and dementia are considered its most common risk factors [2]. During past decades, it was report both in patients taking typical/atypical antipsychotic agents [3] and in idiopathic cases or during neurodegenerative diseases such as Parkinson Disease (PD) [4] and other parkinsonisms [5, 6]. More recently, an association with cholinesterase inhibitors [7], selective serotonin re-uptake inhibitors and other antidepressants [8, 9], antiepileptic as valproic acid [10] or antiparkinsonian agents as dopamine-agonists [11, 12] has been accounted, suggesting a pathophysiological role of cholinergic-dopaminergic imbalance in the regulation of axial muscle tone [13]. To date, only one case of secondary PS unrelated to exposure to psychotropic medications has been reported in a patient with idiopathic normal pressure hydrocephalus (iNPH) in which a dysregulation of dopaminergic pathways has been observed [14]. We report here a case of PS in a patient with subacute subdural haematoma (SDH) that was reverted by evacuation intervention.

Case presentation

A 76 years-old hypertensive man was admitted to the Department of Neurosciences of Neurological Center of Latium in September for recent onset of slowly progressive weakness in left upper limb and postural instability. He also was observed walking with a tilt toward the left during the last week because of slight rotation of the trunk. The patient referred a mild head trauma without loss of consciousness occurred around three months before. No history of major operations, neurological disorders or drug and alcohol abuse was reported. Hypertension was treated by means of ramipril 5 mg/day and amlodipine 10 mg/day for more than 5 years with an optimal control of pressure values. No other previous or current pharmacological interventions were anamnestically retrieved, including with antidepressant, neuroleptic or cholinesterase inhibitors drugs. Family history was negative for neurological disorders other than acute cerebrovascular diseases. Both laboratory studies (liver and kidney function, serum electrolytes, lipids, coagulation, haemachrome) and electrocardiograms were within normal ranges. Neurological examination revealed motor deficits in left hand grip and forearm flexion associated to sustained tonic 15-degrees lateral flexion of the trunk to the left side with slight forward rotation (see Figure 1). Abnormal posture of the trunk worsened in walking and was reduced in lying. We also observed left lateropulsion and difficulty in maintain Romberg position after eyes closure. We did not find significant changes in muscle tone or limb agility impairment, such as cerebellar signs and symptoms were not elicited. Tremor was not present at rest or during action or postural maintaining. Acutely performed cerebral Magnetic Resonance Imaging (MRI) with Diffusion Weighted Imaging (DWI) showed a voluminous right frontal, temporal and parietal subdural haematoma with a diameter of 28 mm. Ipsilateral ventricle was compressed with 8 mm shift of median line (Figure 2). A minimal amount of haematic shedding (3 mm diameter) was also present in left frontal subdural space. In T2-weighted images, some periventricular hyperintense areas and a right cerebellar lacunar focus were observed as probable expression of microvascular pathology. After neurosurgical evaluation, the patient underwent surgical evacuation by means of single burr hole drainage under the local anesthesia and positioning of a soft silicon drain, which was removed within 2 days. Twenty-four hours after the intervention, neurological examination was negative and tonic flexion of the trunk was dramatically improved (Figure 3). We obtained postoperative Computerized Tomography scans within 3 days after surgery that showed a minimal residual hygroma. Four days after intervention, both dystonic deviation and lateropulsion disappeared and the patient was dismissed. No neurological deficit was evident at 12-months follow up, with particular regard of extrapyramidal and cognitive signs or symptoms.

Conclusion

Although the pathophysiology of PS is poorly understood, the implication of monoamines has been widely suggested [13, 15]. According to many Authors, the occurrence of truncal dystonia during several pharmacologic treatments and neurodegenerative disorders (such as Alzheimer disease and parkinsonian syndromes) supported the hypothesis that a complex dysregulation of multiple neurotransmitter systems are involved [13, 16]. Both an excess of cholinergic transmission and a decrease of dopaminergic tone could be implied in some cases because of causative effect of cholinesterase inhibitors and/or antagonist effects of neuroleptics on type-2 dopamine (D2) and type-2 serotonin (5HydroxyTriptamine, 5HT-2) receptors [15]. Down-regulation of postsynaptic norepinephrine (NE) and 5HT-2 receptors induced by antidepressant drugs may also determine a dysfunction of brain stem pathways involved in axial tone control [17]. In parkinsonian syndromes, PS and other lateral truncal dystonia has been related not only to pharmacological treatment, but also to the clinical stage of the disease [18]. An imbalance in the dopaminergic-cholinergic system, depending both on the progression of nigrostriatal pathology and on pharmacological treatment has been postulated in PD [18, 19]. Supporting the neurotransmitters hypothesis, efficacy of anticholinergic drugs and switching therapy to less cholinergic antipsychotics, such as quetiapine or clozapine has been described in some reports [15]. To our knowledgement, this is the first case of secondary PS not related to both pharmacological intervention and neurodegenerative disorders. In our patient, there was no personal or family history of cerebral degenerative disorders or specific previous and current pharmacological treatments other than antihypertensive drugs ramipril and amlodipine. Otherwise MRI revealed wide compression phenomena of subcortical structures and a significative shift of median line. The previously reported case of PS with no previous exposure to specific drugs was related to an iNPH in which brain asymmetry seems to affect neurotransmitters function by means of a downregulation of D2 receptors in the striatum due to nigrostriatal dopaminergic pathways alteration [14, 20, 21]. In this case, a possible role of functional disruption of non-dopaminergic systems such as thalamo-cortical tract through the corona radiata may be hypotized. Experimental results suggest that axial posture impairment in PD are related to progressive loss of propioceptive integration during spatial orientation tasks despite the integrity of vestibular system [22]. Some Authors suggested that an imbalance between control mechanisms of postural orientation and stabilization might explain both dystonic phenomena and instability in PD patients [4, 19, 22]. In our case, tonic flexion of the trunk was indeed associated to left lateropulsion and static and dynamic postural instability suggesting such an impairment of sense of position and more generally a lateralized propioceptive dysfunction [22]. Compressive effect of SDH on the afferent fibers to primary somatosensory cortex from ventral posterolateral nucleus of the thalamus may account for a subtle loss of the sense of position and movement and an impairment of proprioceptive integration resulting in an impairment of the control of body orientation [16, 21]. Furthermore, a complex contribution of basal ganglia in postural control and body rotation may be postulated according to several lesion studies that accounted for uncontrolled axial posture after controlateral lesion of caudate and lenticular nucleus [4, 18]. Displacement of subcortical structure in our patients may alter motor cortex connectivity to basal ganglia with consequent reduction of inhibition pathways to sensory-motor cortex because a particular involvement of unilateral caudate and lenticular nuclei [4, 16, 22].
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Acknowledgments

We thank Marco Salvatori and Daniela Pietrangeli for their contribution in imaging editing and Mr. John Paul Kimes who provided free language assistance and revision.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no financial and non-financial competing interests.

Authors’ contributions

PM performed the preoperative and postoperative clinical evaluation of the patients, collected both literature and patient data and imaging and drafted the manuscript; AS interpreted neuroimaging, carried out neurosurgical intervention as first operator and revised critically the manuscript; MV performed the clinical follow up at one year and helped to collected literature data and to draft the manuscript; Cristiano Giannone carried out the neurosurgical intervention as second operator and helped to draft the manuscript; FDA collected anamnestic data, helped the interpretation of neuroimaging and participated in the manuscript draft; GM interpreted neuroimaging, performed preoperative and postoperative clinical evaluation, revised critically the manuscript and finally approved the version to be published. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Ekbom K, Lindholm H, Ljungberg L: New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972, 202: 94-103.PubMed Ekbom K, Lindholm H, Ljungberg L: New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972, 202: 94-103.PubMed
2.
Zurück zum Zitat Suzuki T, Matsuzaka H: Drug-induced Pisa syndrome (Pleurothotonus): epidemiology and management. CNS Drugs. 2002, 16: 165-174. 10.2165/00023210-200216030-00003.CrossRefPubMed Suzuki T, Matsuzaka H: Drug-induced Pisa syndrome (Pleurothotonus): epidemiology and management. CNS Drugs. 2002, 16: 165-174. 10.2165/00023210-200216030-00003.CrossRefPubMed
3.
Zurück zum Zitat Duggal HS, Sivamony S, Umapathy C: Pisa syndrome and atypical antipsychotics. Am J Psychiatry. 2004, 161: 373-10.1176/appi.ajp.161.2.373.CrossRefPubMed Duggal HS, Sivamony S, Umapathy C: Pisa syndrome and atypical antipsychotics. Am J Psychiatry. 2004, 161: 373-10.1176/appi.ajp.161.2.373.CrossRefPubMed
4.
Zurück zum Zitat Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, Censi D, Barone P, Bovi T, Fasano A: Pisa syndrome in Parkinson’s disease: an electrophysiological and imaging study. J Neurol. 2013, 260 (8): 2138-2148. 10.1007/s00415-013-6945-8.CrossRefPubMed Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, Censi D, Barone P, Bovi T, Fasano A: Pisa syndrome in Parkinson’s disease: an electrophysiological and imaging study. J Neurol. 2013, 260 (8): 2138-2148. 10.1007/s00415-013-6945-8.CrossRefPubMed
5.
Zurück zum Zitat Colosimo C: Pisa syndrome in a patient with multiple system atrophy. Mov Disord. 1998, 13: 607-609. 10.1002/mds.870130342.CrossRefPubMed Colosimo C: Pisa syndrome in a patient with multiple system atrophy. Mov Disord. 1998, 13: 607-609. 10.1002/mds.870130342.CrossRefPubMed
6.
Zurück zum Zitat Solla P, Cannas A, Costantino E, Orofino G, Lavra L, Marrosu F: Pisa syndrome in a patient with progressive supranuclear palsy. J Clin Neurosci. 2012, 19 (6): 922-923. 10.1016/j.jocn.2012.01.018.CrossRefPubMed Solla P, Cannas A, Costantino E, Orofino G, Lavra L, Marrosu F: Pisa syndrome in a patient with progressive supranuclear palsy. J Clin Neurosci. 2012, 19 (6): 922-923. 10.1016/j.jocn.2012.01.018.CrossRefPubMed
7.
Zurück zum Zitat Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R: Pisa syndrome in a cohort of Alzheimer’s disease patients. Acta Neurol Scand. 2005, 111 (3): 199-201. 10.1111/j.1600-0404.2005.00388.x.CrossRefPubMed Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R: Pisa syndrome in a cohort of Alzheimer’s disease patients. Acta Neurol Scand. 2005, 111 (3): 199-201. 10.1111/j.1600-0404.2005.00388.x.CrossRefPubMed
8.
Zurück zum Zitat Arya DK: Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry. 1994, 165: 728-733. 10.1192/bjp.165.6.728.CrossRefPubMed Arya DK: Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry. 1994, 165: 728-733. 10.1192/bjp.165.6.728.CrossRefPubMed
9.
Zurück zum Zitat Suzuki T, Kurita H, Hori T, Sasaki M, Baba A, Shiraishi H, Piletz JE: The Pisa syndrome (Pleurothotonus) during antidepressant therapy. Biol Psychiatry. 1997, 41: 234-236. 10.1016/S0006-3223(96)00405-2.CrossRefPubMed Suzuki T, Kurita H, Hori T, Sasaki M, Baba A, Shiraishi H, Piletz JE: The Pisa syndrome (Pleurothotonus) during antidepressant therapy. Biol Psychiatry. 1997, 41: 234-236. 10.1016/S0006-3223(96)00405-2.CrossRefPubMed
10.
Zurück zum Zitat Yohanan M, Aulakh JS, Weith J, Hawkins JW: Pisa syndrome in a patient in a wheelchair taking Valproic acid. Am J Psychiatry. 2006, 163 (2): 325-326.CrossRefPubMed Yohanan M, Aulakh JS, Weith J, Hawkins JW: Pisa syndrome in a patient in a wheelchair taking Valproic acid. Am J Psychiatry. 2006, 163 (2): 325-326.CrossRefPubMed
11.
Zurück zum Zitat Cannas A, Solla P, Floris G, Tacconi P, Serra A, Piga M, Marrosu F, Marrosu MG: Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy. J Neurol. 2009, 256 (3): 390-395. 10.1007/s00415-009-0072-6.CrossRefPubMed Cannas A, Solla P, Floris G, Tacconi P, Serra A, Piga M, Marrosu F, Marrosu MG: Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy. J Neurol. 2009, 256 (3): 390-395. 10.1007/s00415-009-0072-6.CrossRefPubMed
12.
Zurück zum Zitat Stubner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Möller HJ, Rüther E: Pisa syndrome (Pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 2000, 61 (8): 569-574. 10.4088/JCP.v61n0805.CrossRefPubMed Stubner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Möller HJ, Rüther E: Pisa syndrome (Pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 2000, 61 (8): 569-574. 10.4088/JCP.v61n0805.CrossRefPubMed
13.
Zurück zum Zitat Villarejo A, Camacho A, Garcia-Ramos R, Moreno T, Penas M, Juntas R, Ruiz J: Cholinergic– dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol. 2003, 26: 119-121. 10.1097/00002826-200305000-00004.CrossRefPubMed Villarejo A, Camacho A, Garcia-Ramos R, Moreno T, Penas M, Juntas R, Ruiz J: Cholinergic– dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol. 2003, 26: 119-121. 10.1097/00002826-200305000-00004.CrossRefPubMed
14.
Zurück zum Zitat Leon-Sarmiento FE, Pradilla G, Del Rosario Zambrano M: Primary and Reversible Pisa Syndrome in Juvenile Normal Pressure Hydrocephalus. Acta Neuropsychiatr. 2013, 25 (1): 57-60. 10.1111/j.1601-5215.2012.00657.x.CrossRefPubMed Leon-Sarmiento FE, Pradilla G, Del Rosario Zambrano M: Primary and Reversible Pisa Syndrome in Juvenile Normal Pressure Hydrocephalus. Acta Neuropsychiatr. 2013, 25 (1): 57-60. 10.1111/j.1601-5215.2012.00657.x.CrossRefPubMed
15.
Zurück zum Zitat Suzuki T, Hori T, Baba A, Abe S, Shiraishi H, Moroji T, Piletz JE: Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced Pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol. 1999, 19: 277-280. 10.1097/00004714-199906000-00017.CrossRefPubMed Suzuki T, Hori T, Baba A, Abe S, Shiraishi H, Moroji T, Piletz JE: Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced Pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol. 1999, 19: 277-280. 10.1097/00004714-199906000-00017.CrossRefPubMed
16.
Zurück zum Zitat Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, Bloem BR: Postural deformities in Parkinson’s disease. Lancet Neurol. 2011, 10: 538-549. 10.1016/S1474-4422(11)70067-9.CrossRefPubMed Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, Bloem BR: Postural deformities in Parkinson’s disease. Lancet Neurol. 2011, 10: 538-549. 10.1016/S1474-4422(11)70067-9.CrossRefPubMed
17.
Zurück zum Zitat Remington GJ: The Pisa syndrome: possible role for serotonin and noradrenaline. J Clin Psychopharmacol. 1988, 8: 228-229.CrossRefPubMed Remington GJ: The Pisa syndrome: possible role for serotonin and noradrenaline. J Clin Psychopharmacol. 1988, 8: 228-229.CrossRefPubMed
18.
Zurück zum Zitat Kim JS, Park JW, Chung SW, Kim YI, Kim HT, Lee KS: Pisa syndrome as a motor complication of Parkinson’s disease. Parkinsonism Relat Disord. 2007, 13 (2): 126-128. 10.1016/j.parkreldis.2006.03.010.CrossRefPubMed Kim JS, Park JW, Chung SW, Kim YI, Kim HT, Lee KS: Pisa syndrome as a motor complication of Parkinson’s disease. Parkinsonism Relat Disord. 2007, 13 (2): 126-128. 10.1016/j.parkreldis.2006.03.010.CrossRefPubMed
19.
Zurück zum Zitat Gambarin M, Antonini A, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M: Pisa syndrome without neuroleptic exposure in a patient with Parkinson’s disease: case report. Mov Disord. 2006, 21 (2): 270-273. 10.1002/mds.20711.CrossRefPubMed Gambarin M, Antonini A, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M: Pisa syndrome without neuroleptic exposure in a patient with Parkinson’s disease: case report. Mov Disord. 2006, 21 (2): 270-273. 10.1002/mds.20711.CrossRefPubMed
20.
Zurück zum Zitat Ouchi Y, Nakayama T, Kanno T, Yoshikawa E, Shinke T, Torizuka T: In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus. J Cereb Blood Flow Metab. 2007, 27: 803-810.PubMed Ouchi Y, Nakayama T, Kanno T, Yoshikawa E, Shinke T, Torizuka T: In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus. J Cereb Blood Flow Metab. 2007, 27: 803-810.PubMed
21.
Zurück zum Zitat Kondziella D, Sonnewald U, Tullberg M, Wikkelso C: Brain metabolism in adult chronic hydrocephalus. J Neurochem. 2008, 106: 1515-1524. 10.1111/j.1471-4159.2008.05422.x.CrossRefPubMed Kondziella D, Sonnewald U, Tullberg M, Wikkelso C: Brain metabolism in adult chronic hydrocephalus. J Neurochem. 2008, 106: 1515-1524. 10.1111/j.1471-4159.2008.05422.x.CrossRefPubMed
22.
Zurück zum Zitat Almeida QJ, Frank JS, Roy EA, Jenkins ME, Spaulding S, Patla AE, Jog MS: An evaluation of sensorimotor integration during locomotion toward a target in Parkinson’s disease. Neuroscience. 2005, 134: 283-293. 10.1016/j.neuroscience.2005.02.050.CrossRefPubMed Almeida QJ, Frank JS, Roy EA, Jenkins ME, Spaulding S, Patla AE, Jog MS: An evaluation of sensorimotor integration during locomotion toward a target in Parkinson’s disease. Neuroscience. 2005, 134: 283-293. 10.1016/j.neuroscience.2005.02.050.CrossRefPubMed
Metadaten
Titel
Reversible Pisa syndrome associated to subdural haematoma: case-report
verfasst von
Pasquale Marchione
Aldo Spallone
Marcella Valente
Cristiano Giannone
Floriana De Angelis
Giuseppe Meco
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
BMC Neurology / Ausgabe 1/2014
Elektronische ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-149

Weitere Artikel der Ausgabe 1/2014

BMC Neurology 1/2014 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.